Back to top
more

Innoviva (INVA)

(Delayed Data from NSDQ)

$16.37 USD

16.37
394,864

+0.33 (2.06%)

Updated Jun 6, 2024 04:00 PM ET

After-Market: $16.37 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (144 out of 248)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Innoviva (INVA) Dips More Than Broader Markets: What You Should Know

Innoviva (INVA) closed the most recent trading day at $14.05, moving -0.07% from the previous trading session.

Kinjel Shah headshot

5 Beaten-Down Biotech Stocks Set to Rebound in 2020

Here we discuss some biotech stocks, which are down this year so far but have the potential to bounce back next year.

Should Value Investors Buy Innoviva (INVA) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Mallinckrodt Initiates Phase IV Study on Acthar for Keratitis

Mallinckrodt (MNK) initiates phase IV, multi-center, multiple-dose, open-label study to assess the effects of lead drug Acthar Gel as a therapy option in patients with severe keratitis.

Horizon Therapeutics Eye Drug Gets Positive FDA Advisory Vote

Horizon Therapeutics' (HZNP) pipeline candidate, teprotumumab, gets favorable vote from DODAC of the FDA for the treatment of Thyroid Eye Disease.

BioCryst Submits NDA for Hereditary Angioedema Candidate

BioCryst (BCRX) files a new drug application to the FDA for once-daily berotralstat (BCX7353), which is being developed for the prevention of hereditary angioedema attacks.

VistaGen Up on Fast Track Designation for Anxiety Disorder Drug

The FDA assigns a Fast Track status to VistaGen's (VTGN) neuroactive nasal spray PH94B for the on-demand treatment of social anxiety disorder. Stock surges.

TG Therapeutics' Shares Soar on Positive Early-Stage Data

TG Therapeutics (TGTX) announces positive first clinical data from its once daily, oral, BTK inhibitor, TG-1701, as a single agent and as a triple therapy in combination.

Top Ranked Value Stocks to Buy for December 10th

Here are three stocks with buy rank and strong value characteristics for investors to consider today, December 10th.

Regeneron Reports Initial Data for Multiple Myeloma Drug

Regeneron (REGN) reports initial data for REGN5458, a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory (R/R) multiple myeloma.

Top Ranked Value Stocks to Buy for December 9th

Here are four stocks with buy rank and strong value characteristics for investors to consider today, December 9th

Ra Pharmaceuticals Begins Phase II Study on Autoimmune Drug

Ra Pharmaceuticals (RARX) begins dosing of the first patient in its phase II study of zilucoplan for the treatment of immune-mediated necrotizing myopathy.

Top Ranked Value Stocks to Buy for December 3rd

Here are four stocks with buy rank and strong value characteristics for investors to consider today, December 3rd

Sorrento Turns Down Two All-Cash Takeover Bids, Stock Jumps

Sorrento (SRNE) rejects an all-cash unsolicited acquisition proposal from two unknown biopharmaceutical companies. The stock shoots up.

Alexion Gets Approval for Label Expansion of Soliris in Japan

Alexion (ALXN) gets Japan Ministry of Health, Labour and Welfare's approval for the label expansion of Soliris.

Surging Earnings Estimates Signal Upside for Innoviva (INVA) Stock

Innoviva (INVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Sanghamitra Saha headshot

Value ETFs & Stocks Offering Real Value: 5 Top Picks

A favorable operating backdrop and cheap valuation are leading value stocks higher. Play the trend with these cheap value stocks and ETFs.

Moleculin Files New Patents for Cancer Candidate Annamycin

Moleculin (MBRX) petitions for new patents to cover annamycin, currently being developed for treating patients with relapsed or refractory acute myeloid leukemia. Shares rise.

Celgene (CELG) Hits 52-Week High, Can the Run Continue?

Celgene (CELG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology

The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology

Swarup Gupta headshot

5 Biotech Stocks to Gain From Trade Deal Rally on the Horizon

Trade-war resistant stocks such as biotechs would be the first to benefit from a relief rally.

Earnings Estimates Moving Higher for Innoviva (INVA): Time to Buy?

Innoviva (INVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for May 15th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday

Is Innoviva (INVA) Stock Outpacing Its Medical Peers This Year?

Is (INVA) Outperforming Other Medical Stocks This Year?

3 Reasons Momentum Stock Investors Will Love Innoviva (INVA)

Innoviva (INVA) stock is looking quite impressive for momentum-oriented investors as it has favorable price performance and is also seeing positive estimate revisions.